Yahoo Finance Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended March 2024, Incyte (INCY) reported revenue of $880.89 million, up 8.9% over the same period last year. EPS came in at $0.64, compared to $0.37 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $935.85 million, representing a surprise of -5.87%. The company delivered an EPS surprise of -27.27%, with the consensus EPS estimate being $0.88.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Incyte performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net product revenues- Jakafi: $571.84 million versus $634.32 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -1.4% change.
Net product revenues- Pemazyre: $17.68 million versus the seven-analyst average estimate of $22.12 million. The reported number represents a year-over-year change of -21.4%.
Net product revenues- Iclusig: $30.34 million versus $27.74 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change.
Revenues- Product royalty revenues: $125.97 million versus $111.08 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.
Revenues- Product revenues: $729.92 million compared to the $828.57 million average estimate based on six analysts. The reported number represents a change of +5.3% year over year.
Royalty revenues- Jakavi: $89.60 million compared to the $86.38 million average estimate based on six analysts. The reported number represents a change of +16.8% year over year.
Net product revenues- Opzelura: $85.72 million versus $99.75 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +51.6% change.
Net product revenues- Minjuvi: $23.87 million compared to the $21.94 million average estimate based on six analysts. The reported number represents a change of +264.2% year over year.
Royalty revenues- Olumiant: $30.59 million versus $39.37 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -10.4% change.
Royalty revenues- Tabrecta: $5.23 million versus $5.88 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +25.3% change.
Net product revenues- Zynyz: $0.47 million versus the two-analyst average estimate of $1.27 million.
View all Key Company Metrics for Incyte here>>>
Shares of Incyte have returned -7.2% over the past month versus the Zacks S&P 500 composite's -2.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Incyte Corporation (INCY) : Free Stock Analysis Report
